BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote In favor of Your Favored Pet Consideration Administration - 2FDA approves Wegovy pill for weight loss
- 3High-Suggested Broilers For Your Homes
- 4Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- 5The German series proving subtitles can be sexy — and wildly addictive
- Inconceivable Spots To Stargaze All over The Planet
- Infants will no longer receive hepatitis B vaccine at birth, CDC announces
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- A Manual for the Right SUV for Seniors
- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- From Amateur to Master: My Involvement in Photography
- Immortal Style: Closet Staples for Each Age
- Figure out How to Get the Best Open Record Rewards
